Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-12), Centogene NV's 3-1 Month Momentum % is -0.91%.
The industry rank for Centogene NV's 3-1 Month Momentum % or its related term are showing as below:
CNTGF's 3-1 Month Momentum % is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: -3.57
vs CNTGF: -0.91
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Centogene NV 3-1 Month Momentum % Related Terms
CNTGF vs ISPC, CHEK, FUNI: 3-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, Centogene NV's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Centogene NV 3-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Centogene NV's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Centogene NV's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Centogene NV (CNTGF) has a 3-1 Month Momentum % of -0.91% as of Aug. 12, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Centogene NV and its competitors.
Is Centogene NV's 3-1 Month Momentum % too high?
Centogene NV's current 3-1 Month Momentum % is -0.91%. Overall, Centogene NV has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Centogene NV's 3-1 Month Momentum % compare to ISPC and CHEK?
Centogene NV's 3-1 Month Momentum % of -0.91% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 3-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Centogene NV and its competitors. Centogene NV's current 3-1 Month Momentum % is -0.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Centogene NV stock overvalued right now?
Centogene NV (CNTGF) has a current 3-1 Month Momentum % of -0.91%. The current 3-1 Month Momentum % is -0.91%. Centogene NV's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Centogene NV (CNTGF), the current 3-1 Month Momentum % is -0.91% as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Centogene NV is a United States-based company engaged in data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. The company operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its diagnostics segment provides targeted genetic sequencing and diagnostics services to patients. Its geographic regions are Europe, the Middle East, North America, and Latin America.
12GF Score
Get the complete analysis for CNTGF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNTGF has been successfully added to your 
